Published 2021 | Version v1
Publication Metadata-only

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)

De Angelis, C
Bruzzese, D
Bernardo, A
Baldini, E
Leo, L
Fabi, A
Gamucci, T
De Placido, P
Poggio, F
Russo, S
Forestieri, V
Lauria, R
De Santo, I
Michelotti, A
Del Mastro, L
De Laurentiis, M
Giuliano, M
De Placido, S
Arpino, G
Others:
De Angelis, C
Bruzzese, D
Bernardo, A
Baldini, E
Leo, L
Fabi, A
Gamucci, T
De Placido, P
Poggio, F
Russo, S
Forestieri, V
Lauria, R
De Santo, I
Michelotti, A
Del Mastro, L
De Laurentiis, M
Giuliano, M
De Placido, S
Arpino, G

Description

We evaluated the efficacy and safety of the nontaxane microtubule dynamics inhibitor eribulin plus the humanized anti-VEGF monoclonal antibody bevacizumab in a novel second-line chemotherapy scheme in HER2-negative metastatic breast cancer (MBC) patients progressing after first-line paclitaxel and bevacizumab.

Additional details

Identifiers Origin repository
Created:
April 14, 2023
Modified:
November 30, 2023